• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

eMed CEO resigns

Article

In a move that took the PACS industry by surprise, eMed Technologies announced May 17 the resignation of CEO Caren Mason. The company cited Mason’s long-distance commute from Wisconsin to eMed’s Boston-based headquarters and her

In a move that took the PACS industry by surprise, eMed Technologies announced May 17 the resignation of CEO Caren Mason. The company cited Mason’s long-distance commute from Wisconsin to eMed’s Boston-based headquarters and her responsibilities to family as reasons for her resignation. Since taking the helm in January 2000, Mason led eMed to an improved position within the PACS and networking marketplace. She also bolstered corporate finances by securing $22 million dollars in venture capital investment. The company’s board of directors has initiated a search for Mason’s replacement.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.